IDH1 and acute myeloid leukemia: A pooled analysis of patients enrolled in the VIALE-A phase III trial and the phase Ib trial of venetoclax + AZA in AML showed that patients harboring mutations in IDH1/2 had a higher benefit from receiving the venetoclax combination compared to AZA alone [71].